DEK VACCINES


Associated tags: Government, Fill, DEK, Vaccine, Licensure, Pharmaceutical industry, FDA, Mortality, Disease, Serum Institute of India, Death, African, University of Oxford, Malaria, SII, VPM, All, University, Health

Locations: GHANA, AFRICA

EQS-News: VPM contributes to the successful licensure of the novel malaria vaccine R21/Matrix-MTM for first use in Ghana

Retrieved on: 
Wednesday, May 10, 2023
Vaccine, University of Oxford, DEK, Partnership, University, All, VPM, SII, Malaria, African, Licensure, Death, Serum Institute of India, Disease, Mortality, FDA, Pharmaceutical industry, Health

This synergistic collaboration facilitated the accelerated licensure process in Ghana and is a step forward on the path to ensuring vaccine equity in Africa.

Key Points: 
  • This synergistic collaboration facilitated the accelerated licensure process in Ghana and is a step forward on the path to ensuring vaccine equity in Africa.
  • Malaria is one of the leading causes of pediatric morbidity and mortality in sub-Saharan Africa.
  • R21/Matrix-MTM has emerged as the most effective vaccine against malaria ever produced and shall contribute to alleviating the burden of 600,000 deaths per year.
  • The licensure of the R21/Matrix-M Malaria Vaccine for use in Ghana and Nigeria is a significant milestone in our efforts to combat malaria around the world.